{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T23:26:05Z","timestamp":1778801165561,"version":"3.51.4"},"reference-count":58,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,7,1]],"date-time":"2018-07-01T00:00:00Z","timestamp":1530403200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,6,11]],"date-time":"2018-06-11T00:00:00Z","timestamp":1528675200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"National Natural Science Foundationn of China","award":["81325003"],"award-info":[{"award-number":["81325003"]}]},{"name":"National Natural Science Foundationn of China","award":["81520108003"],"award-info":[{"award-number":["81520108003"]}]},{"name":"National Natural Science Foundationn of China","award":["81670716"],"award-info":[{"award-number":["81670716"]}]},{"name":"National Natural Science Foundationn of China","award":["81201863"],"award-info":[{"award-number":["81201863"]}]},{"name":"Shanghai Commission of Science and Technology","award":["14430723400"],"award-info":[{"award-number":["14430723400"]}]},{"name":"Shanghai Commission of Science and Technology","award":["14140903100"],"award-info":[{"award-number":["14140903100"]}]},{"name":"Shanghai Commission of Science and Technology","award":["16JC1405800"],"award-info":[{"award-number":["16JC1405800"]}]},{"name":"Shanghai Municipal Education Commission Gaofeng Clinical Medicine Grant Support","award":["20152206"],"award-info":[{"award-number":["20152206"]}]},{"name":"Shanghai Municipal Education Commission Gaofeng Clinical Medicine Grant Support","award":["20152208"],"award-info":[{"award-number":["20152208"]}]},{"name":"Multicenter Clinical Research Project by Shanghai Jiao Tong University School of Medicine","award":["DLY201601"],"award-info":[{"award-number":["DLY201601"]}]},{"name":"Clinical Research Plan of SHDC","award":["16CR2017A"],"award-info":[{"award-number":["16CR2017A"]}]},{"name":"Chang Jiang Scholars Program, Innovation Fund Projects of Shanghai Jiao Tong University","award":["BXJ201607"],"award-info":[{"award-number":["BXJ201607"]}]},{"name":"Collaborative Innovation Center of Systems Biomedicine"},{"DOI":"10.13039\/100001384","name":"Samuel Waxman Cancer Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001384","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Genentech Inc."}],"content-domain":{"domain":["ebiomedicine.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["EBioMedicine"],"published-print":{"date-parts":[[2018,7]]},"DOI":"10.1016\/j.ebiom.2018.06.010","type":"journal-article","created":{"date-parts":[[2018,6,21]],"date-time":"2018-06-21T00:28:31Z","timestamp":1529540911000},"page":"94-104","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Immune Characteristics of Chinese Diffuse Large B-Cell Lymphoma Patients: Implications for Cancer Immunotherapies"],"prefix":"10.1016","volume":"33","author":[{"given":"Peng-peng","family":"Xu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chun","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xu","family":"Cao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xia","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hang-jun","family":"Dai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shan","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jian-jun","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shi-jing","family":"Fu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu-xia","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Su-chun","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ron","family":"McCord","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeff","family":"Venstrom","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edith","family":"Szafer-Glusman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth","family":"Punnoose","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Astrid","family":"Kiermaier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gang","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei-li","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ebiom.2018.06.010_bb0005","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1056\/NEJMoa1510665","article-title":"Nivolumab versus Everolimus in advanced renal-cell carcinoma","volume":"373","author":"Motzer","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ebiom.2018.06.010_bb0010","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1056\/NEJMoa1412082","article-title":"Nivolumab in previously untreated melanoma without BRAF mutation","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ebiom.2018.06.010_bb0015","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1200\/JCO.2016.70.1524","article-title":"Pembrolizumab for platinum- and Cetuximab-refractory head and neck Cancer: results from a single-arm, phase II study","volume":"35","author":"Bauml","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ebiom.2018.06.010_bb0020","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1016\/S0140-6736(16)00561-4","article-title":"Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial","volume":"387","author":"Rosenberg","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.ebiom.2018.06.010_bb0025","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S0140-6736(16)32517-X","article-title":"Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial","volume":"389","author":"Rittmeyer","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.ebiom.2018.06.010_bb0030","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","article-title":"Nivolumab versus Docetaxel in advanced nonsquamous non-small-cell lung Cancer","volume":"373","author":"Borghaei","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ebiom.2018.06.010_bb0035","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung Cancer","volume":"375","author":"Reck","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ebiom.2018.06.010_bb0040","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/S1470-2045(16)30167-X","article-title":"Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial","volume":"17","author":"Younes","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ebiom.2018.06.010_bb0045","article-title":"Pembrolizumab in relapsed\/refractory classical hodgkin lymphoma: Primary end point analysis of the phase 2 keynote-087 study","volume":"1107","author":"Moskowitz","year":"2016","journal-title":"ASH Annu Meet Abstr"},{"key":"10.1016\/j.ebiom.2018.06.010_bb0050","doi-asserted-by":"crossref","first-page":"2698","DOI":"10.1200\/JCO.2015.65.9789","article-title":"Nivolumab in patients with relapsed or refractory hematologic malignancy: preliminary results of a phase Ib study","volume":"34","author":"Lesokhin","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ebiom.2018.06.010_bb0055","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1038\/nri1457","article-title":"IDO expression by dendritic cells: tolerance and tryptophan catabolism","volume":"4","author":"Mellor","year":"2004","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.ebiom.2018.06.010_bb0060","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.leukres.2008.06.014","article-title":"Indoleamine 2,3-dioxygenase activity of acute myeloid leukemia cells can be measured from patients' sera by HPLC and is inducible by IFN-gamma","volume":"33","author":"Corm","year":"2009","journal-title":"Leuk Res"},{"key":"10.1016\/j.ebiom.2018.06.010_bb0065","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1593\/neo.04658","article-title":"Eosinophil granulocytes account for indoleamine 2,3-dioxygenase-mediated immune escape in human non-small cell lung cancer","volume":"7","author":"Astigiano","year":"2005","journal-title":"Neoplasia"},{"key":"10.1016\/j.ebiom.2018.06.010_bb0070","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.imlet.2015.11.012","article-title":"Prognostic value of indoleamine 2,3-dioxygenase activity and expression in nasopharyngeal carcinoma","volume":"169","author":"Ben-Haj-Ayed","year":"2016","journal-title":"Immunol Lett"},{"key":"10.1016\/j.ebiom.2018.06.010_bb0075","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1158\/1078-0432.CCR-05-1966","article-title":"Prognostic value of indoleamine 2,3-dioxygenase expression in colorectal cancer: effect on tumor-infiltrating T cells","volume":"12","author":"Brandacher","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ebiom.2018.06.010_bb0080","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.3109\/10428194.2015.1128541","article-title":"Prognostic value of the combination of serum l-kynurenine level and indoleamine 2,3-dioxygenase mRNA expression in acute myeloid leukemia","volume":"57","author":"Hara","year":"2016","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.ebiom.2018.06.010_bb0085","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1038\/sj.bjc.6603477","article-title":"Indoleamine 2,3-dioxygenase is a novel prognostic indicator for endometrial cancer","volume":"95","author":"Ino","year":"2006","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ebiom.2018.06.010_bb0090","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1111\/j.1349-7006.2007.00470.x","article-title":"Expression of indoleamine 2, 3-dioxygenase and the recruitment of Foxp3-expressing regulatory T cells in the development and progression of uterine cervical cancer","volume":"98","author":"Nakamura","year":"2007","journal-title":"Cancer Sci"},{"key":"10.1016\/j.ebiom.2018.06.010_bb0095","doi-asserted-by":"crossref","first-page":"6030","DOI":"10.1158\/1078-0432.CCR-04-2671","article-title":"Indoleamine 2,3-dioxygenase serves as a marker of poor prognosis in gene expression profiles of serous ovarian cancer cells","volume":"11","author":"Okamoto","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ebiom.2018.06.010_bb0100","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/j.jamcollsurg.2007.12.014","article-title":"Expression of indoleamine 2,3-dioxygenase in metastatic pancreatic ductal adenocarcinoma recruits regulatory T cells to avoid immune detection","volume":"206","author":"Witkiewicz","year":"2008","journal-title":"J Am Coll Surg"},{"key":"10.1016\/j.ebiom.2018.06.010_bb0105","doi-asserted-by":"crossref","first-page":"3269","DOI":"10.1158\/1078-0432.CCR-16-2272","article-title":"First-in-human phase I study of the oral inhibitor of Indoleamine 2,3-Dioxygenase-1 Epacadostat (INCB024360) in patients with advanced solid malignancies","volume":"23","author":"Beatty","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ebiom.2018.06.010_bb0110","doi-asserted-by":"crossref","first-page":"9014","DOI":"10.1200\/JCO.2017.35.15_suppl.9014","article-title":"Efficacy and safety of epacadostat plus pembrolizumab treatment of NSCLC: preliminary phase I\/II results of ECHO-202\/KEYNOTE-037","volume":"35","author":"Gangadhar","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ebiom.2018.06.010_bb0115","doi-asserted-by":"crossref","first-page":"4515","DOI":"10.1200\/JCO.2017.35.15_suppl.4515","article-title":"Epacadostat plus pembrolizumab in patients with advanced RCC: preliminary phase I\/II results from ECHO-202\/KEYNOTE-037","volume":"35","author":"Lara","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ebiom.2018.06.010_bb0120","doi-asserted-by":"crossref","first-page":"6010","DOI":"10.1200\/JCO.2017.35.15_suppl.6010","article-title":"Epacadostat plus pembrolizumab in patients with SCCHN: preliminary phase I\/II results from ECHO-202\/KEYNOTE-037","volume":"35","author":"Hamid","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ebiom.2018.06.010_bb0125","doi-asserted-by":"crossref","first-page":"4503","DOI":"10.1200\/JCO.2017.35.15_suppl.4503","article-title":"Epacadostat plus pembrolizumab in patients with advanced urothelial carcinoma: preliminary phase I\/II results of ECHO-202\/KEYNOTE-037","volume":"35","author":"Smith","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ebiom.2018.06.010_bb0130","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1200\/JCO.2017.35.15_suppl.1103","article-title":"Efficacy\/safety of epacadostat plus pembrolizumab in triple-negative breast cancer and ovarian cancer: phase I\/II ECHO-202 study","volume":"35","author":"Spira","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ebiom.2018.06.010_bb0135","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1002\/j.1460-2075.1990.tb08211.x","article-title":"Characterization of the MRC OX40 antigen of activated CD4 positive T lymphocytes\u2014a molecule related to nerve growth factor receptor","volume":"9","author":"Mallett","year":"1990","journal-title":"EMBO J"},{"key":"10.1016\/j.ebiom.2018.06.010_bb0140","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1002\/eji.1830260805","article-title":"OX40 is differentially expressed on activated rat and mouse T cells and is the sole receptor for the OX40 ligand","volume":"26","author":"Al-Shamkhani","year":"1996","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.ebiom.2018.06.010_bb0145","doi-asserted-by":"crossref","first-page":"4821","DOI":"10.4049\/jimmunol.172.8.4821","article-title":"Costimulation of CD8 T cell responses by OX40","volume":"172","author":"Bansal-Pakala","year":"2004","journal-title":"J Immunol"},{"key":"10.1016\/j.ebiom.2018.06.010_bb0150","doi-asserted-by":"crossref","first-page":"3992","DOI":"10.1002\/j.1460-2075.1994.tb06715.x","article-title":"Molecular characterization of murine and human OX40\/OX40 ligand systems: identification of a human OX40 ligand as the HTLV-1-regulated protein gp34","volume":"13","author":"Baum","year":"1994","journal-title":"EMBO J"},{"key":"10.1016\/j.ebiom.2018.06.010_bb0155","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1084\/jem.191.2.201","article-title":"Role of OX40 signals in coordinating CD4 T cell selection, migration, and cytokine differentiation in T helper (Th)1 and Th2 cells","volume":"191","author":"Lane","year":"2000","journal-title":"J Exp Med"},{"key":"10.1016\/j.ebiom.2018.06.010_bb0160","doi-asserted-by":"crossref","first-page":"7189","DOI":"10.1158\/0008-5472.CAN-12-4174","article-title":"OX40 is a potent immune-stimulating target in late-stage cancer patients","volume":"73","author":"Curti","year":"2013","journal-title":"Cancer Res"},{"key":"10.1016\/j.ebiom.2018.06.010_bb0165","doi-asserted-by":"crossref","first-page":"34","DOI":"10.3389\/fonc.2015.00034","article-title":"OX40 agonists and combination immunotherapy: putting the pedal to the metal","volume":"5","author":"Linch","year":"2015","journal-title":"Front Oncol"},{"key":"10.1016\/j.ebiom.2018.06.010_bb0170","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/35000501","article-title":"Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling","volume":"403","author":"Alizadeh","year":"2000","journal-title":"Nature"},{"key":"10.1016\/j.ebiom.2018.06.010_bb0175","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1056\/NEJMoa0802885","article-title":"Stromal gene signatures in large-B-cell lymphomas","volume":"359","author":"Lenz","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ebiom.2018.06.010_bb0180","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1056\/NEJMoa012914","article-title":"The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma","volume":"346","author":"Rosenwald","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ebiom.2018.06.010_bb0185","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1146\/annurev-immunol-020711-075027","article-title":"Pathogenesis of human B cell lymphomas","volume":"30","author":"Shaffer","year":"2012","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.ebiom.2018.06.010_bb0190","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1182\/asheducation-2013.1.575","article-title":"Understanding MYC-driven aggressive B-cell lymphomas: pathogenesis and classification","volume":"2013","author":"Ott","year":"2013","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.ebiom.2018.06.010_bb0195","doi-asserted-by":"crossref","first-page":"2253","DOI":"10.1182\/blood-2012-06-435842","article-title":"MYC status in concert with BCL2 and BCL6 expression predicts outcome in diffuse large B-cell lymphoma","volume":"121","author":"Horn","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.ebiom.2018.06.010_bb0200","doi-asserted-by":"crossref","first-page":"3452","DOI":"10.1200\/JCO.2011.41.0985","article-title":"Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone","volume":"30","author":"Johnson","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ebiom.2018.06.010_bb0205","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1016\/S0140-6736(16)00587-0","article-title":"Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial","volume":"387","author":"Fehrenbacher","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.ebiom.2018.06.010_bb0210","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/nature14011","article-title":"Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients","volume":"515","author":"Herbst","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.ebiom.2018.06.010_bb0215","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1126\/science.aaa1348","article-title":"Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer","volume":"348","author":"Rizvi","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.ebiom.2018.06.010_bb0220","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1126\/science.aan6733","article-title":"Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade","volume":"357","author":"Le","year":"2017","journal-title":"Science"},{"key":"10.1016\/j.ebiom.2018.06.010_bb0225","doi-asserted-by":"crossref","first-page":"2415","DOI":"10.1056\/NEJMoa1613493","article-title":"First-line Nivolumab in stage IV or recurrent non-small-cell lung Cancer","volume":"376","author":"Carbone","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ebiom.2018.06.010_bb0230","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1016\/S1470-2045(17)30422-9","article-title":"Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study","volume":"18","author":"Overman","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ebiom.2018.06.010_bb0235","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2017.35.15_suppl.e14508","article-title":"Comprehensive genomic profiling to identify tumor mutational burden (TMB) as an independent predictor of response to immunotherapy in diverse cancers","volume":"35","author":"Goodman","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ebiom.2018.06.010_bb0240","doi-asserted-by":"crossref","first-page":"3462","DOI":"10.1158\/1078-0432.CCR-13-0855","article-title":"PD-L1 expression is characteristic of a subset of aggressive B-cell lymphomas and virus-associated malignancies","volume":"19","author":"Chen","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ebiom.2018.06.010_bb0245","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1038\/leu.2012.83","volume":"26","author":"Visco","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.ebiom.2018.06.010_bb0250","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2015.33.15_suppl.8536","article-title":"Development of the molecular diagnostic (MDx) DLBCL lymphoma subtyping test (LST) on the nCounter analysis system","volume":"33","author":"Wallden","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ebiom.2018.06.010_bb0255","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1023\/A:1023949509487","article-title":"Consensus clustering: a resampling-based method for class discovery and visualization of gene expression microarray data","volume":"52","author":"Monti","year":"2003","journal-title":"Mach Learn"},{"key":"10.1016\/j.ebiom.2018.06.010_bb0260","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1182\/blood-2003-05-1545","article-title":"Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray","volume":"103","author":"Hans","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.ebiom.2018.06.010_bb0265","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1038\/leu.2015.57","article-title":"IL10 receptor is a novel therapeutic target in DLBCLs","volume":"29","author":"Beguelin","year":"2015","journal-title":"Leukemia"},{"key":"10.1016\/j.ebiom.2018.06.010_bb0270","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S0140-6736(16)32517-X","article-title":"Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial","volume":"389","author":"Rittmeyer","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.ebiom.2018.06.010_bb0275","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1182\/blood-2004-07-2947","article-title":"Molecular profiling of diffuse large B-cell lymphoma identifies robust subtypes including one characterized by host inflammatory response","volume":"105","author":"Monti","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.ebiom.2018.06.010_bb0280","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1158\/1078-0432.CCR-15-1507","article-title":"The where, the when, and the how of immune monitoring for Cancer immunotherapies in the era of checkpoint inhibition","volume":"22","author":"Hegde","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ebiom.2018.06.010_bb0285","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1126\/science.aac9935","article-title":"MYC regulates the antitumor immune response through CD47 and PD-L1","volume":"352","author":"Casey","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.ebiom.2018.06.010_bb0290","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1016\/S0140-6736(15)01281-7","article-title":"Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial","volume":"387","author":"Herbst","year":"2016","journal-title":"Lancet"}],"container-title":["EBioMedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352396418302172?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352396418302172?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,10,19]],"date-time":"2019-10-19T16:02:03Z","timestamp":1571500923000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352396418302172"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7]]},"references-count":58,"alternative-id":["S2352396418302172"],"URL":"https:\/\/doi.org\/10.1016\/j.ebiom.2018.06.010","relation":{},"ISSN":["2352-3964"],"issn-type":[{"value":"2352-3964","type":"print"}],"subject":[],"published":{"date-parts":[[2018,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immune Characteristics of Chinese Diffuse Large B-Cell Lymphoma Patients: Implications for Cancer Immunotherapies","name":"articletitle","label":"Article Title"},{"value":"EBioMedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ebiom.2018.06.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}